Literature DB >> 311004

Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.

B S Mitchell, E Mejias, P E Daddona, W N Kelley.   

Abstract

Deoxyadenosine at low concentrations and in the presence of an inhibitor of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) is markedly toxic to lymphoblast cell lines of T cell origin but does not impair growth of B cell lines. Deoxyguanosine is also more toxic for T lymphoblasts. In the presence of deoxyadenosine or deoxyguanosine, elevation of the corresponding deoxyribonucleoside triphosphate (dATP or dGTP) occurs in T cell, but not in B cell, lines. The addition of deoxycytidine or dipyridamole results in lower dATP and dGTP levels and prevents deoxyribonucleoside toxicity. These findings provide a molecular basis for the immunodeficiency observed in individuals with several inborn errors of purine metabolism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 311004      PMCID: PMC336252          DOI: 10.1073/pnas.75.10.5011

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Further studies on the effect of deoxyadenosine on the accumulation of deoxyadenosine triphosphate and inhibition of deoxyribonucleic acid synthesis in Ehrlich ascites tumor cells in vitro.

Authors:  H KLENOW
Journal:  Biochim Biophys Acta       Date:  1962-12-31

2.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

3.  Adenosine deaminase activity in lymphocytes.

Authors:  J L Sullivan; W R Osborne; R J Wedgewood
Journal:  Br J Haematol       Date:  1977-09       Impact factor: 6.998

4.  Deoxyadenosine metabolism and toxicity in cultured L5178Y cells.

Authors:  J K Lowe; B Gowans; L Brox
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

5.  Identification and quantitation of adenine deoxynucleotides in erythrocytes of a patient with adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  M S Coleman; J Donofrio; J J Hutton; L Hahn; A Daoud; B Lampkin; J Dyminski
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

6.  A role for purine metabolism in the immune response: Adenosine-deaminase activity and deoxyadenosine catabolism.

Authors:  H A Simmonds; G S Panayi; V Corrigall
Journal:  Lancet       Date:  1978-01-14       Impact factor: 79.321

7.  Severe combined immunodeficiency with B lymphocytes: in vitro correction of defective immunoglobulin production by addition of normal T lymphocytes.

Authors:  R C Seeger; R A Robins; R H Stevens; R B Klein; D J Waldman; P M Zeltzer; S W Kessler
Journal:  Clin Exp Immunol       Date:  1976-10       Impact factor: 4.330

8.  Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase.

Authors:  A Cohen; D Doyle; D W Martin; A J Ammann
Journal:  N Engl J Med       Date:  1976-12-23       Impact factor: 91.245

9.  Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency.

Authors:  J W Stoop; B J Zegers; G F Hendrickx; L H van Heukelom; G E Staal; P K de Bree; S K Wadman; R E Ballieux
Journal:  N Engl J Med       Date:  1977-03-24       Impact factor: 91.245

10.  Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency.

Authors:  A Cohen; R Hirschhorn; S D Horowitz; A Rubinstein; S H Polmar; R Hong; D W Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

View more
  50 in total

1.  Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto-5'-nucleotidase (CD73).

Authors:  R Resta; S W Hooker; A B Laurent; S M Jamshedur Rahman; M Franklin; T B Knudsen; N L Nadon; L F Thompson
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

2.  Adenosine and deoxyadenosine induces apoptosis in oestrogen receptor-positive and -negative human breast cancer cells via the intrinsic pathway.

Authors:  M Hashemi; F Karami-Tehrani; S Ghavami; S Maddika; M Los
Journal:  Cell Prolif       Date:  2005-10       Impact factor: 6.831

3.  Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.

Authors:  Kumudha Balakrishnan; Jan A Burger; Maite P Quiroga; Marina Henneberg; Mary L Ayres; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

4.  Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

Authors:  S Seto; C J Carrera; M Kubota; D B Wasson; D A Carson
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

5.  Adenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulation.

Authors:  C Justin Van De Wiele; James G Vaughn; Michael R Blackburn; Catherine A Ledent; Marlene Jacobson; Hong Jiang; Linda F Thompson
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

6.  Distribution of 5'-nucleotidase in human lymphoid tissues.

Authors:  N L Edwards; E W Gelfand; L Burk; H M Dosch; I H Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

7.  Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines.

Authors:  D A Carson; J Kaye; S Matsumoto; J E Seegmiller; L Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

8.  Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines.

Authors:  E H Chen; E E Johnson; S M Vetter; B S Mitchell
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Isotope-dilution analysis of the effects of deoxyguanosine and deoxyadenosine on the incorporation of thymidine and deoxycytidine by hydroxyurea-treated thymus cells.

Authors:  F W Scott; D R Forsdyke
Journal:  Biochem J       Date:  1980-09-15       Impact factor: 3.857

10.  Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency.

Authors:  M R Aust; L G Andrews; M J Barrett; C J Norby-Slycord; M L Markert
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.